Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Interest Expenses (2016 - 2019)

Historic Interest Expenses for Fate Therapeutics (FATE) over the last 7 years, with Q4 2019 value amounting to $586000.0.

  • Fate Therapeutics' Interest Expenses rose 3502.3% to $586000.0 in Q4 2019 from the same period last year, while for Sep 2020 it was $586000.0, marking a year-over-year decrease of 6444.17%. This contributed to the annual value of $1.8 million for FY2019, which is 588.24% up from last year.
  • Per Fate Therapeutics' latest filing, its Interest Expenses stood at $586000.0 for Q4 2019, which was up 3502.3% from $400000.0 recorded in Q3 2019.
  • Fate Therapeutics' Interest Expenses' 5-year high stood at $600000.0 during Q1 2015, with a 5-year trough of $212000.0 in Q2 2017.
  • For the 5-year period, Fate Therapeutics' Interest Expenses averaged around $432473.7, with its median value being $412000.0 (2017).
  • Per our database at Business Quant, Fate Therapeutics' Interest Expenses surged by 204285.71% in 2015 and then tumbled by 5126.44% in 2017.
  • Over the past 5 years, Fate Therapeutics' Interest Expenses (Quarter) stood at $600000.0 in 2015, then tumbled by 45.17% to $329000.0 in 2016, then rose by 25.23% to $412000.0 in 2017, then increased by 5.34% to $434000.0 in 2018, then soared by 35.02% to $586000.0 in 2019.
  • Its Interest Expenses was $586000.0 in Q4 2019, compared to $400000.0 in Q3 2019 and $409000.0 in Q2 2019.